Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

A dispute over a Duchenne gene therapy highlights thorny issues surrounding FDA approvals and insurance policies.

Biotin and collagen are nutrients that support hair, skin, nail, and bone health. A healthcare provider may suggest taking ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.

The number of confirmed patients in an outbreak of infections from the Cyclospora parasite continues to increase, with 60 ...

Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.

The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s division ...